What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Long-acting amylin analog
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing Cagrilintide inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
Cagrilintide is a 37-amino-acid long-acting amylin analog (Novo Nordisk development code NN9838) engineered with a fatty-acid lipidation strategy analogous to Semaglutide's, producing an albumin-binding profile that supports once-weekly subcutaneous dosing. The molecule activates both the amylin receptor and the calcitonin receptor family, complementing GLP-1-pathway signaling on appetite, gastric emptying, and energy balance. Cagrilintide's primary clinical context is the CagriSema combination with Semaglutide, where the amylin-axis and GLP-1-axis mechanisms produce additive weight-reduction signals beyond either component alone, the basis for Novo Nordisk's REDEFINE Phase 3 program. PeptideXpo supplies lyophilized Cagrilintide acetate at ≥99.0% HPLC with batch-specific COA. For buyers building CagriSema combinations, PeptideXpo can supply either the standalone Cagrilintide vials for in-house ratio blending or pre-blended CagriSema vials co-lyophilized at the buyer's specified ratio (the dedicated CagriSema SKU). Co-lyophilization is preferred over solution-phase mixing because amylin-class peptides have a documented sensitivity to surface-mediated aggregation when held in dilute aqueous solution prior to filling.
Who buys this, and why
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
Documentation available on request
Regulatory note
Investigational compound (Novo Nordisk NN9838); not approved as a finished drug at the time of writing. Sold as a bulk active for research and, in markets where regulations permit, for compounding-pharmacy use. The CagriSema combination is in Phase 3 development.
Frequently asked questions
Amylin and GLP-1 are two distinct signaling axes that both feed into appetite regulation and metabolic control, but through complementary mechanisms, amylin acts on the area postrema and the calcitonin-receptor family, while GLP-1 acts on the GLP-1 receptor in the arcuate nucleus and peripheral targets. Combining them (the CagriSema strategy) produces additive effects on satiety, gastric emptying, and weight reduction that exceed either mechanism alone. The Phase 2 readouts that supported moving CagriSema into Phase 3 development showed weight-reduction signals materially larger than Semaglutide monotherapy at equivalent dose-equivalents.
It depends on the buyer's downstream workflow. Research labs doing dose-response or receptor-pharmacology work generally want standalone Cagrilintide to retain the freedom to vary the ratio in their own experiments. Compounding pharmacies and OEM brands building a finished CagriSema product should order pre-blended vials co-lyophilized at the target ratio (the dedicated CagriSema SKU), co-lyophilization is more potency-stable than solution-phase mixing and the analytical packet certifies the actual ratio on the released vial, not just the theoretical ratio.
Amylin and its analogues have a documented sensitivity to surface-mediated aggregation in dilute aqueous solution, the same biology that drives native amylin to form fibrils in the pancreas. Lyophilized Cagrilintide is stable under the standard 24-month -20 °C re-test spec, but reconstituted solutions should be used promptly, held in low-bind plasticware where possible, and avoided as long-term frozen working stocks. For preparations that need a longer hold, splitting into single-use aliquots immediately after reconstitution is essential, repeat freeze-thaw is the dominant cause of measured-potency loss.
Related peptides
